[Dalbavancin: pharmacokinetic and pharmacodynamic parameters]

Area of Science:

• Pharmacology
• Infectious Diseases

Background:

• Dalbavancin is a novel lipoglycopeptide antibiotic.
• Its pharmacokinetic profile dictates its intravenous administration and distribution.

Purpose of the Study:

• To describe the pharmacokinetic profile of dalbavancin.
• To elucidate its dosing regimen and necessary adjustments in specific patient populations.

Main Methods:

• Analysis of dalbavancin's absorption, distribution, metabolism, and excretion.
• Evaluation of its pharmacokinetic parameters, including half-life and clearance.
• Assessment of dose adjustments in renal and hepatic impairment.

Main Results:

• Dalbavancin exhibits high plasma protein binding and distributes to tissues like skin and bone, but not brain/CSF.
• It has a long terminal elimination half-life (>300 hours), supporting a unique dosing schedule.
• No dose adjustment is needed for mild-moderate renal impairment or hemodialysis; reduced doses are recommended for severe renal impairment without dialysis.

Conclusions:

• Dalbavancin's slow elimination supports its extended dosing regimen.
• Pharmacokinetic variability is low, and interactions are minimal.
• Specific dose reductions are required for certain chronic renal insufficiency patients.